Downloads
Abstract
To assess the clinical and OS, PFS the treatment gastrointestinal stromal tumours (GISTs), relative to
current standard treatments.
Patient and Method:
A prospective study of 74 patients who had diagnosic GISTs (c–KIT), treatments by Imatinib mesylate
(Glivec) since 2013 to 2019 at Oncology Center – Hue Central Hospital
Results:
The age of 56 - 65 years old is high (39.2%); The mean age 56.54 ± 10.47 years (29-84 years). Male:
Female = 1: 1.3. Disseminated abdominal pain accounts for 66.2%; The onset of time is 4.31 ± 3.11
months (1- 13 months). Large invasive stomach tumors 41%, Liver metastasis met 41.9%, abdominal
45,2% among metastatic diseases.
PR : 32.4%; SD : 48.6%; CR 4.1%; OR: 85.1%
Progression free survival (PFS)
- Time mean 38.4 ± 2.73 months (33.1 – 43.78 months).
- Time median 39 ± 6.67 months
-Survival 02 year 65.1%; 03 year 51%; 05 year 22.9%.
Overall survival (OS)
- Time mean 37.6 ± 2.7 months ( 2.3 – 42.9 months)
- Time median 37 ± 5.9 months
- Survival 02 year 63.8%; 03 year 48.15; 05 year 21.8%.
Survival by risk
- Medium risk: Time mean 39.7 ± 3.6 months, the rate of 2 years 67.55%, 03 years 51.9% and 05
years 22.8%
- High risk: Time mean of 34,6 ± 4,1 months, rate of 2 years 58.7%, 03 years 43.5% and 05 years
11.9%.
The difference is not statistically significant p = 0.26
Conclusion: Imatinib mesylate (Glivec) combine with surgical in gastrointestinal stromal tumours (GIST)
was few side effects and improved survival time.
Key words: Gastrointestinal stromal tumours (GISTs), Imatinib mesylate (Glivec)
References
Lê Tuấn Anh, Vương Đinh Thy Hảo và CS
(2015) “Tính an toàn và hiệu quả của Imatinib
mesylate trong điều trị bướu mô đệm đường tiêu
hóa giai đoạn tiến xa tại Bệnh viện Chợ Rẫy”.
Tạp chí Ung thư học, số 01 -2015, tr 246- 252.
Bhalgami R1
, Manish K, et al (2013) “Clinicopathological study of 113 gastrointestinal stromal tumors” Indian J Gastroenterol. 32(1):22-7.
Carvajal Balaguera J. Martin Garcia- Alamenta
M, et al ( 2007) “ Gastrointestinal Stromal Turmors : An infrequent disease with difficult preoperative diagnosis” The Internet journal of Surgery, 13 (1). P 216 – 225.
Dasanu CA1
( 2012) “Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs”. J Oncol Pharm
Pract. 18(3): 379-80.
DeMatteo RP1
, Ballman KV, et al (2013)
“Long-term results of adjuvant imatinib
mesylate in localized, high-risk, primary
gastrointestinal stromal tumor: ACOSOG
Z9000 (Alliance) intergroup phase 2 trial.” Ann
Surg. ;258(3):422-9.
El. Hanafy E, El Hemaly M et al (2011) “ Surgery management of gastric Gastrointestinal
Stromal Turmors a single center experience”
Saudi J gastroenterol 17 (3), 189 – 193.
Hou YY1
, Grabellus F et al (2009)” Impact of
KIT and PDGFRA gene mutations on prognosis
of patients with gastrointestinal stromal tumors
after complete primary tumor resection”. J
Gastrointest Surg. 13(9):1583-92.
Joensuu H1
, Eriksson M, et al (2012) “ One vs
three years of adjuvant imatinib for operable
gastrointestinal stromal tumor: a randomized
trial”. JAMA. 2012 Mar 28;307(12):1265-72.
Kim KH1
, Kim MC, et al ( 2012) “ Long
term survival results for gastric GIST:
is laparoscopic surgery for large
gastric GISTfeasible?”. Ann Surg Oncol.
;10:230
Li J1
, Dang YZ, et al (2013) “ Efficacy observation on imatinib adjuvant therapy with longer
duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence”.
Zhonghua Wei Chang Wai Ke Za Zhi. 2013
Mar;16(3):216-20
Liang YM1
, Li XH, et al (2007) “ Prognostic sig
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2019 Journal of Clinical Medicine Hue Central Hospital